Mechanisms of Rhinovirus Induced Asthma Exacerbations
|ClinicalTrials.gov Identifier: NCT01159782|
Recruitment Status : Unknown
Verified July 2010 by Imperial College London.
Recruitment status was: Recruiting
First Posted : July 9, 2010
Last Update Posted : July 23, 2010
We, the investigators, hypothesise that there are distinct gene profiles in rhinovirus-induced acute exacerbations of asthma. We further hypothesise that these changes in gene expression involve both known mediators of the asthma phenotype as well as other molecules not previously associated with asthma.
The primary objective of this study is to use gene array analysis to determine differentially expressed genes in bronchial epithelial cells and alveolar macrophages from normal and asthmatic subjects before and during rhinovirus infection in vivo. A secondary objective is to determine whether any altered expressions are related to symptom severity, virus load, lung function or airway inflammation in vivo.
We plan to recruit 45 subjects: 15 healthy volunteers, 15 asthmatics naïve to inhaled corticosteroid therapy, and 15 asthmatics on inhaled corticosteroids who will undergo two bronchoscopies, one prior to infection with rhinovirus and the second 4 days post inoculation. Bronchial brushings, biopsies and bronchoalveolar lavage (BAL) will be performed. RNA will be extracted with TRIzol reagent (Invitrogen, Carlsbad, CA) and purified by passage through RNeasy columns (Qiagen, Valencia, CA). Exon 1.0ST array chips (Affymetrix, Santa Clara, CA) will be used to analyse changes in gene expression. These are the most powerful genome expression tools available with 1.4 million probe sets and over 5.5 million features per array. Genes found to be significantly upregulated will be confirmed by quantitative RT-PCR.
Using a novel method of collecting undiluted bronchial epithelial lining fluid (bronchosorption) large numbers of proteins will be measured with a MesoScale Discovery multiplexed array system (MesoScale Discovery, Gaithersburg, Md) allowing further confirmation of the gene array results as well as providing in vivo evidence of dysregulated protein production in asthmatics. Gene expression and protein levels will be correlated with viral load, symptom scores, lung function and airway inflammation in vivo.
This study represents the first comprehensive evaluation of changes in bronchial epithelial gene expression during rhinovirus infection in vivo and therefore has the potential to provide significant insights into the host response in asthma and identify potential novel targets for further evaluation.
|Condition or disease||Intervention/treatment||Phase|
|Rhinovirus Infection in Asthma||Other: Rhinovirus infection||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||45 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Human Model of Rhinovirus Induced Acute Asthma Exacerbations|
|Study Start Date :||October 2009|
|Estimated Primary Completion Date :||April 2012|
|Estimated Study Completion Date :||April 2012|
Asthmatics or Healthy Volunteers
Other: Rhinovirus infection
All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
- differentially expressed genes in bronchial epithelial cells and alveolar macrophages from normal and asthmatic subjects before and during rhinovirus infection [ Time Frame: april 2012 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01159782
|National Heart and Lung Institute||Recruiting|
|London, England, United Kingdom, W2 1PG|
|Contact: David Jackson email@example.com|
|Principal Investigator: Sebastian Johnston|